Mabwell Bioscience Receives Regulatory Clearance to Initiate Human Trials for Investigational Drug 6MW5311

Stock News

06/23

Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it has received a clinical trial approval notice from the National Medical Products Administration.

The approval pertains to the investigational new drug application for 6MW5311 injection, intended for the treatment of hematologic malignancies, including acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma.

6MW5311 is a bispecific antibody targeting LILRB4 and CD3, developed utilizing the company's T Cell Engager technology platform, and is being developed for these specific blood cancer indications.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1178147278"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178147278\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178147278?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178147278","market":"sh","top_or_hot":-1,"title":"Mabwell Bioscience Receives Regulatory Clearance to Initiate Human Trials for Investigational Drug 6MW5311","media":"Stock News","content":"<p>Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it has received a clinical trial approval notice from the National Medical Products Administration.<br><br>The approval pertains to the investigational new drug application for 6MW5311 injection, intended for the treatment of hematologic malignancies, including acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma.<br><br>6MW5311 is a bispecific antibody targeting LILRB4 and CD3, developed utilizing the company's T Cell Engager technology platform, and is being developed for these specific blood cancer indications.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mabwell Bioscience Receives Regulatory Clearance to Initiate Human Trials for Investigational Drug 6MW5311</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMabwell Bioscience Receives Regulatory Clearance to Initiate Human Trials for Investigational Drug 6MW5311\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-23 18:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it has received a clinical trial approval notice from the National Medical Products Administration.<br><br>The approval pertains to the investigational new drug application for 6MW5311 injection, intended for the treatment of hematologic malignancies, including acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma.<br><br>6MW5311 is a bispecific antibody targeting LILRB4 and CD3, developed utilizing the company's T Cell Engager technology platform, and is being developed for these specific blood cancer indications.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688062","symbol_name":"迈威生物-U","start_time":0,"source_url":"","article_id":"1178147278","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178147278","pubTimestamp":1782211223,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it has received a clinical trial approval notice from the National Medical Products Administration.The approval pertains to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688062":"迈威生物-U","BK0239":"医药制造","BK1161":"生物科技","02493":"迈威生物-B"},"translate_title":"Mabwell Bioscience获得监管部门批准启动研究药物6MW5311人体试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688062":1,"02493":1},"content_text":"Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it has received a clinical trial approval notice from the National Medical Products Administration.The approval pertains to the investigational new drug application for 6MW5311 injection, intended for the treatment of hematologic malignancies, including acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma.6MW5311 is a bispecific antibody targeting LILRB4 and CD3, developed utilizing the company's T Cell Engager technology platform, and is being developed for these specific blood cancer indications.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}